Our mission is to ensure the generation of accurate and precise findings.
Please enter subscribe form shortcode
Please enter instagram feed shortcode
CarboHyde is advancing a pipeline of wholly-owned carbohydrate-based API candidates that address a number of diseases with high unmet needs or other novel applications.
We are a group of passionate cyclodextrins-lovers who realize that there is a need for targeted industrial experience in advancing and broadening innovative projects. The company has a solid pipeline of some moonshot applications, including gene therapy and biotechnology, yet it also supports other companies and groups who seek cyclodextrin expertise. The company fosters several preclinical programs in various neurodegenerative and rare disease indications, superior ways of delivering oligonucleotides, and various applications related to vaccines while continuously working on exploring novel applications as well.
Our purpose is to bring cyclodextrin-based innovations to the market.
a key opinion leader in cyclodextrin chemistry, initiator, and supporter of innovation
a pharma company with at least one dozen internal projects partnered and unpartnered
the holder of 5+ patent families for different compounds and sponsor of early-stage clinical trials
“The heart of CarboHyde beats with an extraordinary collective knowledge base. Our team boasts a harmonious blend of experts in cyclodextrin chemistry, analytical methods, formulation development, drug delivery, GMP manufacturing, marketing, and commercialization. This unparalleled synergy positions CarboHyde as the only entity with such a diverse and integrated spectrum of expertise in the field of cyclodextrins.”
HQ – Labs & Offices Located in the European Union – Budapest, Hungary The staff of researchers trained in carbohydrate chemistry, manufacturing, formulation, and analysis. We believe that the importance of serving patients is superior to our internal goals, thus CarboHyde team is happy to assist other companies in their cyclodextrin-related developments.
Scientific Objective 1:
a precise inhibition of the expression of cancer-associated glycans thus affecting their functional role in cancer progression;
Scientific Objective 2:
the development of cutting-edge tools that target those key cancer-associated glycans that are uniquely expressed on cancer cells
GENEGUT has one primary ambition: to create a first-of-its-kind, game-changing treatment for ileal Crohn’s Disease, addressing a significant unmet medical need, by making major advances in RNA-delivery technology to inflamed sites in the gut following oral administration.
In May 2023 the Bicyclos project has been selected for funding in the frame of the Marie Sklodowska-Curie Actions, that are part of the Excellence Pillar of the Horizon Europe Research and Innovation Programme. Bicyclos is a Staff Exchange project involving 9 beneficiaries and 2 associated partners. The full title of the project is «Breaking down barriers to foster new Cyclodextrin-based applications for healthcare by implementing sustainable design principles». So, it’s all about Cyclodextrins, a fascinating class of molecules.